South Rampart Pharma Successfully Completes Phase 1 Study and Expands Phase 2 Plans to Include Neuropathic and Acute Pain Trials
January 2, 2024 Phase 1 data demonstrate that SRP-001 exhibits
January 2, 2024 Phase 1 data demonstrate that SRP-001 exhibits
November 1, 2023 South Rampart’s Global Intellectual Property Portfolio Now
Oct. 12, 2023 The Fast Track designation accelerates SRP-001's path
October 10, 2023 - BIO Investor Forum taking place on
Sept. 21, 2023 The NIH's CRP Award Further Validates the
August 22, 2023 - SRP-001, a novel, non-opioid investigational drug
July 6, 2023 South Rampart's global intellectual property portfolio now
Jan. 31, 2023 Hernan Bazan, MD, FACS, CEO and Co-Founder,
Oct. 21, 2022 South Rampart Pharma ("South Rampart" or the
Oct. 4, 2022 - New patent grant further secures South Rampart's